Global Monoclonal antibodies (mAbs) Biosimilars Market 2024 by Company, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global Monoclonal antibodies (mAbs) Biosimilars market size was valued at USD 4812.9 million in 2023 and is forecast to a readjusted size of USD 5470.7 million by 2030 with a CAGR of 1.8% during review period.
A biosimilar medicine is a medicinal product of biological origin that is produced in a living organism following a procedure equivalent to a biological drug and adhering to the same quality criteria, hence the name biosimilars. In short, they are biological drugs that are “equivalent” in terms of quality, efficacy and safety to an innovative reference medicinal product.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Monoclonal antibodies (mAbs) Biosimilars industry chain, the market status of Anti-Cancer (Erythropoietin (EPO), Human Growth Hormone (HGH)), Anti-Inflammatory/Autoimmune (Erythropoietin (EPO), Human Growth Hormone (HGH)), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Monoclonal antibodies (mAbs) Biosimilars.
Regionally, the report analyzes the Monoclonal antibodies (mAbs) Biosimilars markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Monoclonal antibodies (mAbs) Biosimilars market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Monoclonal antibodies (mAbs) Biosimilars market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Monoclonal antibodies (mAbs) Biosimilars industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Erythropoietin (EPO), Human Growth Hormone (HGH)).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Monoclonal antibodies (mAbs) Biosimilars market.
Regional Analysis: The report involves examining the Monoclonal antibodies (mAbs) Biosimilars market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Monoclonal antibodies (mAbs) Biosimilars market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Monoclonal antibodies (mAbs) Biosimilars:
Company Analysis: Report covers individual Monoclonal antibodies (mAbs) Biosimilars players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Monoclonal antibodies (mAbs) Biosimilars This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Anti-Cancer, Anti-Inflammatory/Autoimmune).
Technology Analysis: Report covers specific technologies relevant to Monoclonal antibodies (mAbs) Biosimilars. It assesses the current state, advancements, and potential future developments in Monoclonal antibodies (mAbs) Biosimilars areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Monoclonal antibodies (mAbs) Biosimilars market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Monoclonal antibodies (mAbs) Biosimilars market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Chapter 1, to describe Monoclonal antibodies (mAbs) Biosimilars product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Monoclonal antibodies (mAbs) Biosimilars, with revenue, gross margin and global market share of Monoclonal antibodies (mAbs) Biosimilars from 2019 to 2024.
Chapter 3, the Monoclonal antibodies (mAbs) Biosimilars competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Monoclonal antibodies (mAbs) Biosimilars market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Monoclonal antibodies (mAbs) Biosimilars.
Chapter 13, to describe Monoclonal antibodies (mAbs) Biosimilars research findings and conclusion.
A biosimilar medicine is a medicinal product of biological origin that is produced in a living organism following a procedure equivalent to a biological drug and adhering to the same quality criteria, hence the name biosimilars. In short, they are biological drugs that are “equivalent” in terms of quality, efficacy and safety to an innovative reference medicinal product.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Monoclonal antibodies (mAbs) Biosimilars industry chain, the market status of Anti-Cancer (Erythropoietin (EPO), Human Growth Hormone (HGH)), Anti-Inflammatory/Autoimmune (Erythropoietin (EPO), Human Growth Hormone (HGH)), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Monoclonal antibodies (mAbs) Biosimilars.
Regionally, the report analyzes the Monoclonal antibodies (mAbs) Biosimilars markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Monoclonal antibodies (mAbs) Biosimilars market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Monoclonal antibodies (mAbs) Biosimilars market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Monoclonal antibodies (mAbs) Biosimilars industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Erythropoietin (EPO), Human Growth Hormone (HGH)).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Monoclonal antibodies (mAbs) Biosimilars market.
Regional Analysis: The report involves examining the Monoclonal antibodies (mAbs) Biosimilars market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Monoclonal antibodies (mAbs) Biosimilars market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Monoclonal antibodies (mAbs) Biosimilars:
Company Analysis: Report covers individual Monoclonal antibodies (mAbs) Biosimilars players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Monoclonal antibodies (mAbs) Biosimilars This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Anti-Cancer, Anti-Inflammatory/Autoimmune).
Technology Analysis: Report covers specific technologies relevant to Monoclonal antibodies (mAbs) Biosimilars. It assesses the current state, advancements, and potential future developments in Monoclonal antibodies (mAbs) Biosimilars areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Monoclonal antibodies (mAbs) Biosimilars market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Monoclonal antibodies (mAbs) Biosimilars market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- Erythropoietin (EPO)
- Human Growth Hormone (HGH)
- Granulocyte- Colony Stimulating Factor (G-CSF)
- Monoclonal Antibody (mAb)
- Insulin
- Interferon (IFN)
- Others
- Anti-Cancer
- Anti-Inflammatory/Autoimmune
- Biocon
- Celltrion
- Dr. Reddy's Laboratories
- Hospira
- 3SBio
- Accord Healthcare
- AET Biotech
- Allergan
- Amega Biotech
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Monoclonal antibodies (mAbs) Biosimilars product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Monoclonal antibodies (mAbs) Biosimilars, with revenue, gross margin and global market share of Monoclonal antibodies (mAbs) Biosimilars from 2019 to 2024.
Chapter 3, the Monoclonal antibodies (mAbs) Biosimilars competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Monoclonal antibodies (mAbs) Biosimilars market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Monoclonal antibodies (mAbs) Biosimilars.
Chapter 13, to describe Monoclonal antibodies (mAbs) Biosimilars research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Monoclonal antibodies (mAbs) Biosimilars
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Monoclonal antibodies (mAbs) Biosimilars by Type
1.3.1 Overview: Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Monoclonal antibodies (mAbs) Biosimilars Consumption Value Market Share by Type in 2023
1.3.3 Erythropoietin (EPO)
1.3.4 Human Growth Hormone (HGH)
1.3.5 Granulocyte- Colony Stimulating Factor (G-CSF)
1.3.6 Monoclonal Antibody (mAb)
1.3.7 Insulin
1.3.8 Interferon (IFN)
1.3.9 Others
1.4 Global Monoclonal antibodies (mAbs) Biosimilars Market by Application
1.4.1 Overview: Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Anti-Cancer
1.4.3 Anti-Inflammatory/Autoimmune
1.5 Global Monoclonal antibodies (mAbs) Biosimilars Market Size & Forecast
1.6 Global Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast by Region
1.6.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region, (2019-2030)
1.6.3 North America Monoclonal antibodies (mAbs) Biosimilars Market Size and Prospect (2019-2030)
1.6.4 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size and Prospect (2019-2030)
1.6.6 South America Monoclonal antibodies (mAbs) Biosimilars Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 Biocon
2.1.1 Biocon Details
2.1.2 Biocon Major Business
2.1.3 Biocon Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.1.4 Biocon Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Biocon Recent Developments and Future Plans
2.2 Celltrion
2.2.1 Celltrion Details
2.2.2 Celltrion Major Business
2.2.3 Celltrion Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.2.4 Celltrion Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Celltrion Recent Developments and Future Plans
2.3 Dr. Reddy's Laboratories
2.3.1 Dr. Reddy's Laboratories Details
2.3.2 Dr. Reddy's Laboratories Major Business
2.3.3 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.3.4 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Dr. Reddy's Laboratories Recent Developments and Future Plans
2.4 Hospira
2.4.1 Hospira Details
2.4.2 Hospira Major Business
2.4.3 Hospira Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.4.4 Hospira Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Hospira Recent Developments and Future Plans
2.5 3SBio
2.5.1 3SBio Details
2.5.2 3SBio Major Business
2.5.3 3SBio Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.5.4 3SBio Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 3SBio Recent Developments and Future Plans
2.6 Accord Healthcare
2.6.1 Accord Healthcare Details
2.6.2 Accord Healthcare Major Business
2.6.3 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.6.4 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Accord Healthcare Recent Developments and Future Plans
2.7 AET Biotech
2.7.1 AET Biotech Details
2.7.2 AET Biotech Major Business
2.7.3 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.7.4 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 AET Biotech Recent Developments and Future Plans
2.8 Allergan
2.8.1 Allergan Details
2.8.2 Allergan Major Business
2.8.3 Allergan Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.8.4 Allergan Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Allergan Recent Developments and Future Plans
2.9 Amega Biotech
2.9.1 Amega Biotech Details
2.9.2 Amega Biotech Major Business
2.9.3 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.9.4 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Amega Biotech Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Monoclonal antibodies (mAbs) Biosimilars Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Monoclonal antibodies (mAbs) Biosimilars by Company Revenue
3.2.2 Top 3 Monoclonal antibodies (mAbs) Biosimilars Players Market Share in 2023
3.2.3 Top 6 Monoclonal antibodies (mAbs) Biosimilars Players Market Share in 2023
3.3 Monoclonal antibodies (mAbs) Biosimilars Market: Overall Company Footprint Analysis
3.3.1 Monoclonal antibodies (mAbs) Biosimilars Market: Region Footprint
3.3.2 Monoclonal antibodies (mAbs) Biosimilars Market: Company Product Type Footprint
3.3.3 Monoclonal antibodies (mAbs) Biosimilars Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Monoclonal antibodies (mAbs) Biosimilars Consumption Value and Market Share by Type (2019-2024)
4.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Monoclonal antibodies (mAbs) Biosimilars Consumption Value Market Share by Application (2019-2024)
5.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Type (2019-2030)
6.2 North America Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Application (2019-2030)
6.3 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country
6.3.1 North America Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Country (2019-2030)
6.3.2 United States Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
6.3.3 Canada Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
6.3.4 Mexico Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Type (2019-2030)
7.2 Europe Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Application (2019-2030)
7.3 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country
7.3.1 Europe Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Country (2019-2030)
7.3.2 Germany Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
7.3.3 France Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
7.3.5 Russia Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
7.3.6 Italy Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region
8.3.1 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Region (2019-2030)
8.3.2 China Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
8.3.3 Japan Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
8.3.4 South Korea Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
8.3.5 India Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
8.3.7 Australia Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Type (2019-2030)
9.2 South America Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Application (2019-2030)
9.3 South America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country
9.3.1 South America Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Country (2019-2030)
9.3.2 Brazil Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
9.3.3 Argentina Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country
10.3.1 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Country (2019-2030)
10.3.2 Turkey Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
10.3.4 UAE Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 Monoclonal antibodies (mAbs) Biosimilars Market Drivers
11.2 Monoclonal antibodies (mAbs) Biosimilars Market Restraints
11.3 Monoclonal antibodies (mAbs) Biosimilars Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Monoclonal antibodies (mAbs) Biosimilars Industry Chain
12.2 Monoclonal antibodies (mAbs) Biosimilars Upstream Analysis
12.3 Monoclonal antibodies (mAbs) Biosimilars Midstream Analysis
12.4 Monoclonal antibodies (mAbs) Biosimilars Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Monoclonal antibodies (mAbs) Biosimilars
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Monoclonal antibodies (mAbs) Biosimilars by Type
1.3.1 Overview: Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Monoclonal antibodies (mAbs) Biosimilars Consumption Value Market Share by Type in 2023
1.3.3 Erythropoietin (EPO)
1.3.4 Human Growth Hormone (HGH)
1.3.5 Granulocyte- Colony Stimulating Factor (G-CSF)
1.3.6 Monoclonal Antibody (mAb)
1.3.7 Insulin
1.3.8 Interferon (IFN)
1.3.9 Others
1.4 Global Monoclonal antibodies (mAbs) Biosimilars Market by Application
1.4.1 Overview: Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Anti-Cancer
1.4.3 Anti-Inflammatory/Autoimmune
1.5 Global Monoclonal antibodies (mAbs) Biosimilars Market Size & Forecast
1.6 Global Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast by Region
1.6.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region, (2019-2030)
1.6.3 North America Monoclonal antibodies (mAbs) Biosimilars Market Size and Prospect (2019-2030)
1.6.4 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size and Prospect (2019-2030)
1.6.6 South America Monoclonal antibodies (mAbs) Biosimilars Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 Biocon
2.1.1 Biocon Details
2.1.2 Biocon Major Business
2.1.3 Biocon Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.1.4 Biocon Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Biocon Recent Developments and Future Plans
2.2 Celltrion
2.2.1 Celltrion Details
2.2.2 Celltrion Major Business
2.2.3 Celltrion Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.2.4 Celltrion Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Celltrion Recent Developments and Future Plans
2.3 Dr. Reddy's Laboratories
2.3.1 Dr. Reddy's Laboratories Details
2.3.2 Dr. Reddy's Laboratories Major Business
2.3.3 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.3.4 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Dr. Reddy's Laboratories Recent Developments and Future Plans
2.4 Hospira
2.4.1 Hospira Details
2.4.2 Hospira Major Business
2.4.3 Hospira Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.4.4 Hospira Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Hospira Recent Developments and Future Plans
2.5 3SBio
2.5.1 3SBio Details
2.5.2 3SBio Major Business
2.5.3 3SBio Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.5.4 3SBio Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 3SBio Recent Developments and Future Plans
2.6 Accord Healthcare
2.6.1 Accord Healthcare Details
2.6.2 Accord Healthcare Major Business
2.6.3 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.6.4 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Accord Healthcare Recent Developments and Future Plans
2.7 AET Biotech
2.7.1 AET Biotech Details
2.7.2 AET Biotech Major Business
2.7.3 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.7.4 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 AET Biotech Recent Developments and Future Plans
2.8 Allergan
2.8.1 Allergan Details
2.8.2 Allergan Major Business
2.8.3 Allergan Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.8.4 Allergan Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Allergan Recent Developments and Future Plans
2.9 Amega Biotech
2.9.1 Amega Biotech Details
2.9.2 Amega Biotech Major Business
2.9.3 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Product and Solutions
2.9.4 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Amega Biotech Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Monoclonal antibodies (mAbs) Biosimilars Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Monoclonal antibodies (mAbs) Biosimilars by Company Revenue
3.2.2 Top 3 Monoclonal antibodies (mAbs) Biosimilars Players Market Share in 2023
3.2.3 Top 6 Monoclonal antibodies (mAbs) Biosimilars Players Market Share in 2023
3.3 Monoclonal antibodies (mAbs) Biosimilars Market: Overall Company Footprint Analysis
3.3.1 Monoclonal antibodies (mAbs) Biosimilars Market: Region Footprint
3.3.2 Monoclonal antibodies (mAbs) Biosimilars Market: Company Product Type Footprint
3.3.3 Monoclonal antibodies (mAbs) Biosimilars Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Monoclonal antibodies (mAbs) Biosimilars Consumption Value and Market Share by Type (2019-2024)
4.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Monoclonal antibodies (mAbs) Biosimilars Consumption Value Market Share by Application (2019-2024)
5.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Type (2019-2030)
6.2 North America Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Application (2019-2030)
6.3 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country
6.3.1 North America Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Country (2019-2030)
6.3.2 United States Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
6.3.3 Canada Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
6.3.4 Mexico Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Type (2019-2030)
7.2 Europe Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Application (2019-2030)
7.3 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country
7.3.1 Europe Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Country (2019-2030)
7.3.2 Germany Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
7.3.3 France Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
7.3.5 Russia Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
7.3.6 Italy Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region
8.3.1 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Region (2019-2030)
8.3.2 China Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
8.3.3 Japan Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
8.3.4 South Korea Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
8.3.5 India Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
8.3.7 Australia Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Type (2019-2030)
9.2 South America Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Application (2019-2030)
9.3 South America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country
9.3.1 South America Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Country (2019-2030)
9.3.2 Brazil Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
9.3.3 Argentina Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country
10.3.1 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Consumption Value by Country (2019-2030)
10.3.2 Turkey Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
10.3.4 UAE Monoclonal antibodies (mAbs) Biosimilars Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 Monoclonal antibodies (mAbs) Biosimilars Market Drivers
11.2 Monoclonal antibodies (mAbs) Biosimilars Market Restraints
11.3 Monoclonal antibodies (mAbs) Biosimilars Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Monoclonal antibodies (mAbs) Biosimilars Industry Chain
12.2 Monoclonal antibodies (mAbs) Biosimilars Upstream Analysis
12.3 Monoclonal antibodies (mAbs) Biosimilars Midstream Analysis
12.4 Monoclonal antibodies (mAbs) Biosimilars Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
